MetaCap

Rapport Therapeutics (RAPP) vs Sarepta Therapeutics (SRPT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rapport Therapeutics (RAPP) has outperformed Sarepta Therapeutics (SRPT) over the past year, losing 15.0% versus a loss of 24.6%. Sarepta Therapeutics is the larger company by market cap ($1.43 billion vs $1.37 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RAPP-15.01%SRPT-24.65%
+99%+34%-31%
Nov 21, 20251 yearNov 20, 2026
RAPP+11.35%SRPT-89.19%
+146%+22%-102%
Jun 3, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RAPP versus SRPT key metrics
MetricRAPPSRPT
Share price$23.16$13.33
Market cap$1.37B$1.43B
1-day change-1.82%-5.93%
YTD return-23.67%-38.06%
1-year return-15.01%-24.65%
5-year return—-83.26%
P/E ratio (TTM)—666.50
Forward P/E—8.87
EPS (TTM)$-3.17$0.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.20B
Revenue growth (YoY)—+15.58%
Net income (latest FY)$-111.48M$-713.41M
Gross margin—98.84%
Operating margin—-31.83%
Net margin—-32.45%
52-week high$52.93$24.68
52-week low$22.06$13.25
Distance from 52-week high-56.24%-45.99%
Analyst consensusstrong_buyhold
Avg. price target upside+177.25%+63.32%
Average volume790.62K2.70M
Shares outstanding59.28M107.24M
Employees84835
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Rapport Therapeutics

RAPP stock →

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees

About Sarepta Therapeutics

SRPT stock →

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.

Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees

RAPP vs SRPT FAQ

Which is bigger, Rapport Therapeutics or Sarepta Therapeutics?

Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.43B compared with $1.37B for Rapport Therapeutics (RAPP).

Which stock has performed better over the past year, RAPP or SRPT?

RAPP returned -15.01% over the past 12 months, compared with -24.65% for SRPT (price return, excluding dividends). Past performance does not predict future results.

Are Rapport Therapeutics and Sarepta Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons